Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

PRIMARY OBJECTIVES:

I. To assess safety and tolerability of combined checkpoint blockade with MEDI4736
(durvalumab) and tremelimumab alone or with high or low-dose radiation in non-small cell lung
cancer (NSCLC). (NSCLC Cohort) II. To compare the overall response (excluding the irradiated
lesion[s]) between combined checkpoint blockade with MEDI4736 and tremelimumab alone or
combined checkpoint blockade with low or high dose radiation. (NSCLC Cohort) III. To assess
safety and tolerability of combined checkpoint blockade with MEDI4736 and tremelimumab with
high or low-dose radiation. (Colorectal Cohort) IV. To determine the overall response rate
(excluding the irradiated lesion[s]) with combined checkpoint blockade with MEDI4736 and
tremelimumab with either low or high dose radiation. (Colorectal Cohort)

SECONDARY OBJECTIVES:

I. To estimate median progression-free survival and overall survival. (NSCLC Cohort) II. To
determine local control within the irradiated field(s) and abscopal response rates. (NSCLC
Cohort) III. To evaluate associations between PD-L1 expression as well as levels of
infiltrating CD3+, CD8+ T-cells and overall response. (NSCLC Cohort) IV. To explore changes
in PD-L1 expression, circulating T-cell populations, T-cell infiltration, ribonucleic acid
(RNA) expression, spatial relationship of immune markers, and mutational burden as a result
of low or high dose radiation. (NSCLC Cohort) V. To estimate median progression-free survival
and overall survival. (Colorectal Cohort) VI. To determine local control within the
irradiated field and abscopal response rates. (Colorectal Cohort) VII. To evaluate
associations between PD-L1 expression as well as levels of infiltrating CD3+ CD8+ T-cells and
overall response. (Colorectal Cohort) VIII. To evaluate changes between PD-L1 expression as
well as levels of infiltrating CD3+, CD8+ T-cells induced by targeted low or high dose
radiation. (Colorectal Cohort) IX. To explore changes in circulating T-cell populations,
T-cell infiltration, RNA expression, spatial relationship of immune markers, and mutational
burden as a result of low or high dose radiation. (Colorectal Cohort)

OUTLINE: Patients with NSCLC are randomized to Arm A, B, or C. Patients with colorectal
cancer are randomized to Arm B or C.

COHORT 1: Patients with NSCLC are randomized to 1 of 3 arms.

ARM A: Patients receive tremelimumab intravenously (IV) and durvalumab IV over 60 minutes
every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable
toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination
dose for up to 9 additional doses.

ARM B: Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2,
patients receive high dose radiation therapy once per day (QD) over 10 days for up to 3
fractions.

ARM C: Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2,
patients receive low dose radiation therapy every 6 hours twice per day (BID) on weeks 2, 6,
10 and 14.

After completion of study treatment, patients are followed for up to 12 weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed non-small cell lung
cancer (cohort 1) or colorectal cancer (cohort 2)

- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with
conventional techniques or as >= 10 mm (>= 1.5 cm) with spiral computed tomography
(CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam

- Patients in both cohorts must have progressive disease following prior therapy;
specifically:

- Cohort 1 (NSCLC): Patients must have evidence of radiologic or clinical disease
progression during previous treatment with systemic PD-1 directed therapy and/or
have been deemed not to derive clinical benefit from PD-1 directed treatment;
this includes patients who demonstrated an initial response and subsequent
progression; no prior treatment with chemotherapy or targeted agents are
required; intervening therapy is allowed between previous PD-1 directed treatment
and there is no required interval from prior PD-1 treatment required; PD-1
directed treatment includes treatment with antibodies targeting the PD-1 receptor
such as pembrolizumab or nivolumab, as well as PD-L1 targeted antibodies such as
MEDI4736 (durvalumab), atezolizumab and avelumab; these agents may have been
administered as part of a clinical trial

- Cohort 2 (colorectal cancer): Patients must have progressed on >= one line
chemotherapy

- At least 21 days must have elapsed from prior systemic therapy (chemotherapy or
radiation)

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 60%)
and life expectancy greater than 6 months; furthermore, enrollment of patients with
greater than 10 measurable lesions is discouraged

- Patients must have normal organ and marrow function independent of transfusion for at
least 7 days prior to screening and independent of growth factor support for at least
14 days prior to screening

- Hemoglobin (Hgb) >= 9 g/dl

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin =< 1.5 x normal institutional limits; this will not apply to patients
with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia
[predominantly unconjugated bilirubin] in the absence of evidence of hemolysis or
hepatic pathology), who will be allowed in consultation with their physician

- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
= < 2.5 x institutional upper limit of normal; for patients with hepatic metastases,
ALT and AST =< 5 x ULT

- Measured creatinine clearance (CL) > 40 mL/min OR calculated creatinine clearance (CL)
> 40 mL/min as determined by Cockcroft-Gault (using actual body weight)

- Patients must have at least one lesion that has not previously been irradiated (and is
not within a previously radiated field) and for which palliative radiation is
potentially indicated and could be safely delivered at the radiation doses specified
in this protocol; this lesion must not be the only measurable lesion so that it is
still possible to determine the response rate outside of the radiation treatment
field; this lesion must not be within the central nervous system (CNS) (brain or
spinal cord) or requiring urgent or emergent palliative radiation given the timing of
radiation specified on this protocol; furthermore, this lesion:

- For cohort 1 (NSCLC cohort) - the lesion to be irradiated must be in the lung,
lymph nodes, adrenal gland or liver

- For cohort 2 (colorectal cohort) - the lesion to be irradiated must be in the
liver

- Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients is required; women will be considered post-menopausal
if they have been amenorrheic for 12 months without an alternative medical cause; the
following age-specific requirements apply:

- Women < 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy)

- Women >= 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced oophorectomy with last menses > 1 year ago, had
chemotherapy-induced menopause with > 1 year interval since last menses, or
underwent surgical sterilization (bilateral oophorectomy or hysterectomy)

- Females of childbearing potential who are sexually active with a non sterilized male
partner must use at least 1 highly effective method of contraception from the time of
screening and must agree to continue using such precautions for 180 days after the
last dose of durvalumab + tremelimumab combination therapy or 90 days after the last
dose of durvalumab monotherapy; non-sterilized male partners of a female patient must
use male condom plus spermicide throughout this period; cessation of birth control
after this point should be discussed with a responsible physician; not engaging in
sexual activity for the total duration of the drug treatment and the drug washout
period is an acceptable practice; however, periodic abstinence, the rhythm method, and
the withdrawal method are not acceptable methods of birth control; female patients
should also refrain from breastfeeding throughout this period

- Non-sterilized males who are sexually active with a female partner of childbearing
potential must use a male condom plus spermicide from screening through 180 days after
receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days
after receipt of the final dose of durvalumab monotherapy; not engaging in sexual
activity is an acceptable practice; however, occasional abstinence, the rhythm method,
and the withdrawal method are not acceptable methods of contraception; male patients
should refrain from sperm donation throughout this period

- Female partners (of childbearing potential) of male patients must also use a highly
effective method of contraception throughout this period

- Should a woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately

- Ability of a patient or a Legally Authorized Representative (LAR) to understand and
the willingness to sign a written informed consent document

- Body weight > 30 kg

- Must have a life expectancy of at least 12 weeks

- Cohort 1 (NSCLC cohort)

- Ability to undergo a fresh tumor biopsy for the purpose of screening for this
clinical trial (including able and willing to give valid written consent) to
ability or to provide an available archival tumor sample taken less than 3 months
prior to study enrollment (and not obtained prior to progression on a PD-1/PD-L1
inhibitor) if a fresh tumor biopsy is not feasible with an acceptable clinical
risk; tumor lesions used for fresh biopsies should be the same lesions to be
irradiated when possible and should not be the same lesions used as Response
Evaluation Criteria in Solid Tumors (RECIST) target lesions, unless there are no
other lesions accessible; additional, optional archival tumor tissue is also
requested from before the prior PD-1 directed therapy

- Cohort 2 (colorectal cohort)

- Ability to undergo a fresh tumor biopsy for the purpose of screening for this
clinical trial (including able and willing to give valid written consent) to
ability or to provide an available archival tumor sample taken less than 3 months
prior to study enrollment if a fresh tumor biopsy is not feasible with an
acceptable clinical risk; tumor lesions used for fresh biopsies should be the
same lesions to be irradiated when possible and should not be the same lesions
used as RECIST target lesions, unless there are no other lesions accessible

- Microsatellite stable (MSS) tumor as documented by either:

- Immunohistochemistry (IHC) testing that does not suggest loss of MLH-1,
MSH-2, PMS2 or MSH6

- Polymerase chain reaction (PCR) testing that does not suggest microsatellite
instability (MSI)

Exclusion Criteria:

- Patients who have had systemic (chemotherapy, biologic therapy or radiotherapy) within
3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study

- Receipt of prior radiotherapy or condition for any reason that would contribute
radiation dose that would exceed tolerance of normal tissues, at the discretion of the
treating physician

- Patients who have not recovered from adverse events due to prior anti-cancer therapy
(i.e., have residual toxicities > grade 1)

- Patients who are receiving any other investigational agents

- Patients with untreated brain metastases, spinal cord compression, or leptomeningeal
carcinomatosis should be excluded from this clinical trial; patients whose brain
metastases have been treated may participate provided they show radiographic stability
(defined as 2 brain images, both of which are obtained after treatment to the brain
metastases; these imaging scans should both be obtained at least four weeks apart and
show no evidence of intracranial progression); in addition, any neurologic symptoms
that developed either as a result of the brain metastases or their treatment must have
resolved or be stable either, without the use of steroids, or are stable on a steroid
dose of =< 10 mg/day of prednisone or its equivalent (and anti-convulsants) for at
least 14 days prior to the start of treatment

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736
or other PD-1 or PD-L1 directed therapy that led to drug discontinuation

- Prior exposure to immune-mediated therapy, including durvalumab and tremelimumab,
except for anti-PD-1 or anti-PD-L1 therapy (including durvalumab) in NSCLC patients;
this includes anti-CTLA-4 agents (prior treatment with these agents is NOT allowed in
either cohort) and, excludes therapeutic anticancer vaccines, excluding therapeutic
anticancer vaccines; exposure to other investigational agents may be permitted after
discussion with the study principal investigator (PI)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation

- Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab monotherapy or 180 days after
the last dose of durvalumab + tremelimumab combination therapy, whichever is later

- Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate
studies will be undertaken in patients receiving combination antiretroviral therapy
when indicated

- Any concurrent chemotherapy, immune therapy, biologic, hormonal therapy for cancer
treatment

- Current or prior use of immunosuppressive medication within 14 days before the first
dose of their assigned IP; the following are exceptions to this criterion:

- Intranasal, inhaled, topical steroids, or local steroid injections (e.g.,
intra-articular injection)

- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
prednisone or its equivalent

- Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan
pre-medication)

- Major surgical procedure (as defined by the investigator) within 28 days prior to the
first dose of IP; Note: local surgery of isolated lesions for palliative intent is
acceptable

- History of allogeneic organ transplantation

- Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease, diverticulitis [with the exception of diverticulosis];
sarcoidosis syndrome, or other serious gastrointestinal [GI] chronic conditions
associated with diarrhea; systemic lupus erythematosus; Wegener syndrome
[granulomatosis with polyangiitis]; myasthenia gravis; Graves disease; rheumatoid
arthritis; hypophysitis; uveitis, sarcoidosis syndrome, etc.) within the past 3 years
prior to the start of treatment; the following are exceptions to this criterion:

- Patients with vitiligo or alopecia

- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement or psoriasis not requiring systemic treatment

- Any chronic skin condition that does not require systemic therapy

- Patients without active disease in the last 5 years may be included but only
after consultation with the study physician

- Patients with celiac disease controlled by diet alone

- History of another primary malignancy except for

- Malignancy treated with curative intent and with no known active disease >= 5
years before the first dose of study drug and of low potential risk for
recurrence

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease

- Adequately treated carcinoma in situ without evidence of disease (e.g., cervical
cancer in situ)

- Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from
electrocardiograms (ECGs) using Fridericia's correction; abnormal ECGs should be
repeated

- History of active primary immunodeficiency

- Known history of previous clinical diagnosis of tuberculosis

- Active infection including hepatitis B (known positive hepatitis B virus [HBV] surface
antigen [HBsAg]) result or, hepatitis C; patients with a past or resolved HBV
infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence
of HBsAg) are eligible; patients positive for hepatitis C (HCV) antibody are eligible
only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA); negative
serologies documented over the past year are sufficient evidence of this

- Receipt of live, attenuated vaccine within 30 days prior to the first dose of
investigational treatment; Note: patients, if enrolled, should not receive live
vaccine during the study and up to 30 days after the last dose of investigational
treatment

- Any condition that, in the opinion of the investigator, would interfere with evaluati